King Of Prussia, PA, United States
King Of Prussia, PA, United States

Trevena Inc a clinical stage biopharmaceutical company, headquartered in King of Prussia, PA, and is the leader in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's innovative approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. In 2008, the company raised $25 Million in a Series A financing round led by Alta Partners, Polaris Ventures, New Enterprise Associates, Healthcare Ventures, and Yasuda Economic Development Corporation. Trevena was named one of the top 15 US startups of 2008 by Business Week. The company raised an additional $35 million USD in a B round of venture financing in the summer of 2010.Trevena's lead program, TRV027 for acute heart failure, targets the angiotensin receptor utilizing beta-arrestin bias, an approach that has shown numerous beneficial cardiovascular and renal actions in preclinical species. Trevena completed Phase I clinical trials in 2010. Phase 2 clinical trials on TRV027 began in the spring of 2011.Trevena is also developing TRV130, a G protein-biased ligand for the intravenous treatment of acute moderate-to-severe post-operative pain. The Phase I first-in-human clinical trial of TRV130 is complete. The drug was safe and generally well-tolerated in this study, with pharmacodynamic effects recapitulating its exciting preclinical profile. The next clinical study of TRV130 will investigate analgesic efficacy and tolerability, and will include intravenous morphine, a gold-standard post-operative analgesic, as a comparator. Trevena’s expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. In addition to TRV027, Trevena’s pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, and Parkinson’s disease. In early 2009, Trevena entered into a collaborative agreement with Ligand Pharmaceuticals to identify biased ligands at numerous GPCRs from a large, diverse chemical library. Later that year, Trevena received a competitively awarded American Recovery and Reinvestment Act Grand Opportunities Grant, spanning two years and funding $7.65 million USD of research. The company has disclosed specific interests in the mu Opioid receptor and kappa Opioid receptor. In 2011, Treveva received another NIH grant as part of the NIH Blueprint Neurotherapeutics Network, potentially worth up to $10M USD, to support preclinical development of a delta opioid receptor biased ligand for major depressive disorder. Trevena has received funding from the Michael J. Fox Foundation to explore the potential for delta opioid receptor biased ligands to treat Parkinson's disease. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Trevena | Date: 2017-03-29

Embodiments disclosed herein provide compounds and methods for preparing Beta-Arrestin Effectors.


The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.


This application describes a family of compounds acting as -arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.


This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.


Patent
Trevena | Date: 2015-05-19

Embodiments disclosed herein provide compounds and methods for preparing Beta-Arrestin Effectors.


This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.


This application describes a family of compounds acting as -arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.


The present disclosure provides novel crystalline forms of a compound that acts as a -arrestin effector, processes for preparing novel crystalline and amorphous forms of a compound that acts as a -arrestin effector and uses thereof


This application describes compounds acting as, for example, -arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases.


This application describes a family of compounds acting as -arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.

Loading Trevena collaborators
Loading Trevena collaborators